Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway

World Journal of Gastroenterology

Volumn 21, Issue 32, 2015, Pages 9566-9576

  Ding, Qian ^a   Tian, Xiang Guo ^a   Li, Yan ^a   Wang, Qi Zhi ^a   Zhang, Chun Qing ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Adrenergic antagonists; Angiogenesis; Carvedilol; Drug utilization; Liver cirrhosis

Indexed keywords

CARVEDILOL; CHOLECYSTOKININ OCTAPEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TYROSINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; CARBAZOLE DERIVATIVE; KDR PROTEIN, HUMAN; PROPANOLAMINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOASSAY; CELL ACTIVATION; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SIGNALING ASSAY; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; INTRACELLULAR SPACE; LIVER CIRRHOSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSWELL MIGRATION ASSAY; TUBE FORMATION ASSAY; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; ANGIOGENESIS; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT;

ANGIOGENESIS INHIBITORS; CARBAZOLES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIVER CIRRHOSIS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROPANOLAMINES; PROTEIN KINASE INHIBITORS; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84940118745     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i32.9566     Document Type: Article

References (49)

1. Marone G, Granata F. Angiogenesis, lymphangiogenesis and clinical implications. Preface. Chem Immunol Allergy 2014; 99: XI-XII [PMID: 24217613 DOI: 10.1159/000352074]
2. Fernández M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620 [PMID: 19157625 DOI: 10.1016/j.jhep.2008.12.011]
3. Valfrè di Bonzo L, Novo E, Cannito S, Busletta C, Paternostro C, Povero D, Parola M. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009; 24: 1323-1341 [PMID: 19688698]
4. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30: 258-270 [PMID: 20665378 DOI: 10.1055/s-0030-1255355]
5. Varricchi G, Granata F, Loffredo S, Genovese A, Marone G. Angiogenesis and lymphangiogenesis in inflammatory skin disorders. J Am Acad Dermatol 2015; 73: 144-153 [PMID: 25922287 DOI: 10.1016/j.jaad.2015.03.041]
6. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010; 16: 3526-3532 [PMID: 20634194 DOI: 10.1158/1078-0432. ccr-09-1834]
7. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-3290 [PMID: 17496922 DOI: 10.1038/sj.onc.1210421]
8. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-1284 [PMID: 17126425 DOI: 10.1016/j.bbamcr.2006.10.001]
9. Yang F, Li J, Zhu J, Wang D, Chen S, Bai X. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice. Eur J Pharmacol 2015; 754: 105-114 [PMID: 25720342 DOI: 10.1016/j.ejphar.2015.02.015]
10. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651 [PMID: 18550886 DOI: 10.1056/NEJMc0708819]
11. Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010; 53: 200-208 [PMID: 20732454 DOI: 10.1016/j.vph.2010.08.002]
12. Pan SL, Guh JH, Huang YW, Chern JW, Chou JY, Teng CM. Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J Urol 2003; 169: 724-729 [PMID: 12544352 DOI: 10.1097/01. ju.0000037731.83941.db]
13. Keledjian K, Garrison JB, Kyprianou N. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. J Cell Biochem 2005; 94: 374-388 [PMID: 15526277 DOI: 10.1002/jcb.20240]
14. Dietrich P, Moleda L, Kees F, Müller M, Straub RH, Hellerbrand C, Wiest R. Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: impact of exogenous neuropeptide Y. J Hepatol 2013; 58: 254-261 [PMID: 23041305 DOI: 10.1016/j.jhep.2012.09.027]
15. Bristow MR, Larrabee P, Müller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig 1992; 70 Suppl 1: S105-S113 [PMID: 1350478]
16. Feuerstein GZ, Ruffolo RR. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16 Suppl F: 38-42 [PMID: 8521883]
17. Nichols AJ, Gellai M, Ruffolo RR. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 1991; 5: 25-38 [PMID: 1712335]
18. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000; 100: 293-296 [PMID: 10676810]
19. Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994; 59: 520-529 [PMID: 7525492]
20. Lu J, Zhang K, Nam S, Anderson RA, Jove R, Wen W. Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling. Carcinogenesis 2010; 31: 481-488 [PMID: 19969552 DOI: 10.1093/carcin/bgp292]
21. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE. VEGFdependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 2010; 17: 499-512 [PMID: 19834490 DOI: 10.1038/cdd.2009.152]
22. Meissner M, Hrgovic I, Doll M, Kaufmann R. PPARδ agonists suppress angiogenesis in a VEGFR2-dependent manner. Arch Dermatol Res 2011; 303: 41-47 [PMID: 21046127 DOI: 10.1007/s00403-010-1091-y]
23. Ibrahim N, Yu Y, Walsh WR, Yang JL. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncol Rep 2012; 27: 1303-1311 [PMID: 22323095 DOI: 10.3892/or.2012.1675]
24. Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, Baker D, Howard Z, Jackson L, Ratcliffe K, Wainwright A, Lovick SC, Hickinson DM, Wilkinson RW, Barry ST, Speake G, Ryan AJ. Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int J Oncol 2011; 39: 271-278 [PMID: 21537841 DOI: 10.3892/ijo.2011.1022]
25. Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Invest New Drugs 2012; 30: 1501-1510 [PMID: 21567184 DOI: 10.1007/s10637-011-9683-8]
26. Pang X, Yi T, Yi Z, Cho SG, Qu W, Pinkaew D, Fujise K, Liu M. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 2009; 69: 518-525 [PMID: 19147565 DOI: 10.1158/0008-5472.can-08-2531]
27. Asami Y, Kakeya H, Komi Y, Kojima S, Nishikawa K, Beebe K, Neckers L, Osada H. Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activation. Cancer Sci 2008; 99: 1853-1858 [PMID: 18637013 DOI: 10.1111/j.1349-7006.2008.00890.x]
28. Yu X, Zhu J, Mi M, Chen W, Pan Q, Wei M. Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Med Oncol 2012; 29: 349-357 [PMID: 21132400 DOI: 10.1007/s12032-010-9770-2]
29. Berra E, Milanini J, Richard DE, Le Gall M, Viñals F, Gothié E, Roux D, Pagès G, Pouysségur J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000; 60: 1171-1178 [PMID: 11007955]
30. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Hebbel RP. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ ERK and SAPK/JNK signaling. Exp Cell Res 1999; 247: 495-504 [PMID: 10066377 DOI: 10.1006/excr.1998.4359]
31. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003; 301: 94-96 [PMID: 12843393 DOI: 10.1126/science.1082015]
32. Pałgan K, Bartuzi Z. Angiogenesis in bronchial asthma. Int J Immunopathol Pharmacol 2015; Epub ahead of print [PMID: 25875602 DOI: 10.1177/0394632015580907]
33. Amarapurkar AD, Amarapurkar DN, Vibhav S, Patel ND. Angiogenesis in chronic liver disease. Ann Hepatol 2007; 6: 170-173 [PMID: 17786144]
34. Kukla M, Gabriel A, Sabat D, Liszka Ł, Wilk M, Petelenz M, Musialik J, Dzindziora-Frelich I. Association between liver steatosis and angiogenesis in chronic hepatitis C. Pol J Pathol 2010; 61: 154-160 [PMID: 21225498]
35. Sanz-Cameno P, Trapero-Marugán M, Chaparro M, Jones EA, Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010; 2010: 272170 [PMID: 20592752 DOI: 10.1155/2010/272170]
36. Gabriel A, Kukla M, Wilk M, Liszka Ł, Petelenz M, Musialik J. Angiogenesis in chronic hepatitis C is associated with inflammatory activity grade and fibrosis stage. Pathol Res Pract 2009; 205: 758-764 [PMID: 19592175 DOI: 10.1016/j.prp.2009.06.007]
37. Shah VH, Bruix J. Antiangiogenic therapy: not just for cancer anymore? Hepatology 2009; 49: 1066-1068 [PMID: 19330868 DOI: 10.1002/hep.22872]
38. Elpek GÖ. Angiogenesis and liver fibrosis. World J Hepatol 2015; 7: 377-391 [PMID: 25848465 DOI: 10.4254/wjh.v7.i3.377]
39. Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Semin Cancer Biol 2008; 18: 164-170 [PMID: 18201896 DOI: 10.1016/j.semcancer.2007.12.005]
40. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628-638 [PMID: 21317458]
41. Liao X, Che X, Zhao W, Zhang D, Bi T, Wang G. The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling. Oncol Rep 2010; 24: 1669-1676 [PMID: 21042766]
42. Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009; 20: 477-482 [PMID: 19387337 DOI: 10.1097/CAD.0b013e32832bd1e3]
43. Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M. β-blockers increase response to chemotherapy via direct antitumour and antiangiogenic mechanisms in neuroblastoma. Br J Cancer 2013; 108: 2485-2494 [PMID: 23695022 DOI: 10.1038/bjc.2013.205]
44. Liu CP, Jan CR. Effect of carvedilol on Ca2+ movement and cytotoxicity in human MG63 osteosarcoma cells. Basic Clin Pharmacol Toxicol 2004; 95: 59-65 [PMID: 15379781 DOI: 10.1111/j.1742-7843.2004.950203.x]
45. Erguven M, Yazihan N, Aktas E, Sabanci A, Li CJ, Oktem G, Bilir A. Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol 2010; 36: 857-866 [PMID: 20198329]
46. Cheng JS, Huang CC, Chou CT, Jan CR. Mechanisms of carvedilol-induced [Ca2+] i rises and death in human hepatoma cells. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 185-194 [PMID: 17917717 DOI: 10.1007/s00210-007-0191-5]
47. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30: 3-16 [PMID: 20175029 DOI: 10.1055/s-0030-1247128]
48. Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7: 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362]
49. Hamdy N, El-Demerdash E. New therapeutic aspect for carvedilol: antifibrotic effects of carvedilol in chronic carbon tetrachlorideinduced liver damage. Toxicol Appl Pharmacol 2012; 261: 292-299 [PMID: 22543095 DOI: 10.1016/j.taap.2012.04.012]